Apexigen raises $73m to advance immuno-oncology product development

Image: APX005M is a immuno-oncology (I-O) therapeutic currently in multiple phase 2 clinical trials to treat different types of cancers. Photo: courtesy of dream designs / FreeDigitalPhotos.net.